Alphabet (Google) is making another move into the healthcare space. Verily, its life sciences research platform and subsidiary, has announced an agreement to acquire SignalPath for an undisclosed sum. SignalPath is a privately held company that has developed the SignalPath platform, a clinical trial management system (CTMS) that improves the ease, quality and efficiency of conducting clinical research at study sites.
SignalPath’s platform reduces fragmentation by leveraging a modern software architecture with a cloud-based platform to optimize the management of a study site’s clinical trials portfolio. SignalPath’s robust technology infrastructure offers novel approaches to partners that can dramatically improve the costs, complexities and time associated with clinical trials.
The acquisition will strengthen and expand Verily’s existing clinical trial system and evidence generation platform, known as Baseline. SignalPath employees will join Verily as part of Verily’s clinical research business at the time of closing. They will maintain their physical presence in Raleigh, increasing Verily’s geographic footprint with this new location in North Carolina.
Verily last announced a deal in 2017 for Senosis Health, which develops a family of smartphone apps that monitor newborn jaundice, lung function, and blood hemoglobin by using the smartphone’s camera and microphone.
